Arabic Arabic English English French French German German
dark

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the PALISADE study, a Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome (FCS). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Conference Call on Report on Operations 2021

Next Post

Perceval: CORCYM Announces the First Patient Implanted in China

Related Posts
Total
0
Share